Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies.

• Authors : Blauvelt, A. (); Paul, C. (); Kerkhof, P. ()

• Source: British Journal of Dermatology. Apr2021, Vol. 184 Issue 4, p640-651. 12p.

• Abstract: Summary: Background: Certolizumab pegol (CZP) is an Fc‐free, PEGylated anti‐tumour necrosis factor biologic. Objectives: To report 3‐year safety data from three phase III ...

Record details

Expanding the therapeutic options for psoriatic conditions.

• Authors : Lebwohl M; Wong VK; Croce CD

• Source: Patient Care (PATIENT CARE), Aug2007 Allergy/Immunology; 41(18): 6-12. (6p)

Record details

Cochrane Central Register of Controlled Trials

Record details

Cochrane Central Register of Controlled Trials

Record details

Expanding the therapeutic options for psoriatic conditions.

• Authors : Lebwohl M; Wong VK; Della Croce C ...

• Source: Patient Care (PATIENT CARE), Dec2004; 38(12): 46-50. (5p)

Record details

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

• Authors : Lebwohl, M.; Strober, B.; Menter, A.

• Source: New England Journal of Medicine (N ENGL J MED), 10/1/2015; 373(14): 1318-1328. (11p)

Record details

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis.

• Authors : Lebwohl, M.; Thaçi, D.; Warren, R.B.

Subjects: PSORIASIS; TREATMENT effectiveness; DISEASE remissionUNIVERSITY of California, Berkeley

• Source: Journal of the European Academy of Dermatology & Venereology; Feb2021 Supplement S1, Vol. 35, p35-41, 7p

• Abstract: The majority of patients with psoriasis vulgaris (chronic plaque psoriasis) can be treated successfully with short‐term topical therapies. However, long‐term management of psoriasis ... Copyright of Journal of the European Academy of Dermatology & Venereology is the property of Wiley-Blackwell and its content may not be copied or emailed ...

Record details

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY).

• Authors : Bagel, J.; Blauvelt, A.; Nia, J.

Subjects: QUALITY of life; PSORIASIS; SKIN

• Source: Journal of the European Academy of Dermatology & Venereology; Jan2021, Vol. 35 Issue 1, p135-142, 8p

• Abstract: Background: Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks ... Copyright of Journal of the European Academy of Dermatology & Venereology is the property of Wiley-Blackwell and its content may not be copied or emailed ...

Record details

Cochrane Central Register of Controlled Trials

Record details

Cochrane Central Register of Controlled Trials

Record details